Kymera Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Great. Good morning. I'm Eric Joseph, senior biotech analyst with JPMorgan. And our next presenting company is Kymera therapeutics. Presenting on behalf of the Company is CEO, Nello Mainolfi.
(Event Instructions) With that, Nello, thanks for joining us.
Thank you, Eric. Thanks for the invite. Thanks, everybody, for joining. Actually like this room very unique in theater. So I'll spend the next 2025 minutes to just go over a camera story where we are, what we're going on, our data, our ambition and our strategy. So certainly, I think it makes sense to start really we're trying to build here. We believe that we have a once-in-a-generation opportunity to build a company that can change how we think about treatment paradigm using novel modality in this case using targeted protein degradation. I think it's fair to say that we've taken a unique approach to how to building a company on a novel modality I think
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
